Edwin Elmhirst

Data Journalist at Scrip

Data journalist at Citeline

Featured in: Favicon

evaluate.com Favicon

informa.com (+3) Favicon

citeline.com (+1)

Articles

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

1 week ago | insights.citeline.com | Edwin Elmhirst

Defying Gravity: Five Drugs That Surpassed Their Sales ForecastsMany assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.
Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

2 weeks ago | insights.citeline.com | Eleanor Malone |Edwin Elmhirst |Kosh Naran

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay ChartAbbVie’s Outgoing CEO Gonzalez Takes Second Place The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Oncology’s Most Eligible Unpartnered Assets

2 months ago | insights.citeline.com | Edwin Elmhirst

Oncology’s Most Eligible Unpartnered AssetsEvaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
China’s Biotech Stocks Proved More Resilient Than US Amid Market Turmoil

2 months ago | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst |Dexter Yan

China’s Biotech Stocks Proved More Resilient Than US Amid Market TurmoilStart-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
Unpartnered Obesity Assets Are Becoming Slim Pickings For Pharma

Mar 13, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

Unpartnered Obesity Assets Are Becoming Slim Pickings For PharmaEvaluate Pharma’s top 10 list of unpartnered mid-stage obesity assets shows that few credible challengers to Novo’s Wegovy and Lilly’s Zepbound remain available.
After Obesity, What Are Biopharma’s Big Growth Markets?

Feb 27, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

After Obesity, What Are Biopharma’s Big Growth Markets? The five therapy areas forecast to achieve the highest growth between 2024 and 2030 include a mixture of the more obvious (MASH) and less high profile (glioma). In some cases, which companies will seize market share remains up for grabs.
Five Companies Heading Toward 2030 With Wind At Their Back

Feb 26, 2025 | insights.citeline.com | Jessica Merrill |Edwin Elmhirst

Five Companies Heading Toward 2030 With Wind At Their BackWhich Big Companies Face The Least LOE Hit? Novo, Sanofi, Gilead, Lilly and Bayer are among the big pharmas with the fewest expected US exclusivity losses from 2026-2030.
Licensing For Innovation: A Decade Of Pharma Product Deals

Feb 24, 2025 | insights.citeline.com | Edwin Elmhirst

Licensing For Innovation: A Decade Of Pharma Product DealsLicensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
2025’s Biggest New Launches

Feb 19, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

2025’s Biggest New Launches Big pharma once again fails to dominate the top 20 expected best sellers from products due for launch this year. Small-to-medium pharma account for nearly half the list, while Vertex has two products in the top five.
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024

Feb 10, 2025 | insights.citeline.com | Andrew McConaghie |Edwin Elmhirst

Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024Summit Therapeutics hit the stock market heights in 2024, along with a handful of biotech with novel therapies and platforms, while Moderna was dragged down by shrinking COVID-19 vaccine sales.